RxDoctor Payments Data

Helen McGlashen

Family · Phoenix, AZNPI 1568160653

Payments from drug & device makers

$3,185in general payments, 2019–2025

Across 89 payments — averaging $35.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$764
  • AbbVie$356
  • UCB, Inc.$350
  • Amgen$261
  • Johnson & Johnson$250
  • Sanofi$231
  • plus $972 from 12 others

What the payments were for

  • Food & beverage$2,93992%
  • Education$2468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,185 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$129,602
Medicare patients
566
Services billed
2,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate14$27,228
Clobetasol Propionate179$6,076
Fluorouracil71$5,411
Pimecrolimus12$4,431
Ketoconazole194$3,245
Clindamycin Phosphate49$1,644
Metronidazole21$1,067
Triamcinolone Acetonide161$889
Betamethasone Dipropionate16$751
Doxycycline Hyclate36$415
Hydrocortisone66$403
Ciclopirox12$286
Nystatin16$238
ValacyclovirValacyclovir Hcl14$144
Terbinafine Hcl12$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$41$27,22814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →